Berlex ABOVE Study Will Evaluate Switching Avonex MS Patients To Betaseron
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Berlex/Chiron’s ABOVE (Interferon beta-1a vs. Interferon beta-1b Observation of Efficacy) study will evaluate whether there is a benefit to switching relapsing-remitting MS patients from once-weekly treatment with Biogen’s Avonex to Berlex’ more frequently administered and higher-dose Betaseron.
You may also be interested in...
Betaseron Adds Secondary Progressive MS Use; Limited To Relapsing Patients
Berlex/Chiron’s Betaseron indication has been expanded to include secondary progressive multiple sclerosis, but approval is limited to the subset of patients who continue to have relapsing disease.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011